Ipilimumab-associated cholestatic hepatitis: a case report and literature review

Ipilimumab is a monoclonal antibody that exerts its effects by inhibiting the cytotoxic T-lymphocyte-associated protein 4 receptor on cytotoxic T lymphocytes. It is frequently used for the treatment of unresectable or metastatic melanoma. Ipilimumab may lead to several immune-related disease includi...

Full description

Saved in:
Bibliographic Details
Published inMelanoma research Vol. 27; no. 4; p. 380
Main Authors Yildirim, Sümeyra, Deniz, Kemal, Doğan, Ender, Başkol, Mevlüt, Gürsoy, Şebnem, Özkan, Metin
Format Journal Article
LanguageEnglish
Published England 01.08.2017
Subjects
Hepatitis - diagnosis
Humans
Ipilimumab - adverse effects
Male
Melanoma - drug therapy
Melanoma - pathology
Middle Aged
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
Online AccessGet more information

Cover

More Information
Summary:Ipilimumab is a monoclonal antibody that exerts its effects by inhibiting the cytotoxic T-lymphocyte-associated protein 4 receptor on cytotoxic T lymphocytes. It is frequently used for the treatment of unresectable or metastatic melanoma. Ipilimumab may lead to several immune-related disease including colitis, thyroiditis, pneumonia, hepatitis, or pancreatitis as a side effect. Limited number of cases with hepatic damage as an ipilimumab-related adverse event has been reported in the literature. This agent has been implicated in causing acute hepatitis-like liver injury. Here, we presented a case in which cholestatic hepatitis developed during ipilimumab use for the treatment of metastatic melanoma.
ISSN:1473-5636
DOI:10.1097/CMR.0000000000000366